In doing so, the vaccine successfully expanded DC/iNKT cell/naïve CD8+ T cell interactions, thereby efficiently priming and expanding Ag-specific CD8+ T cells as intended, and ultimately enhanced a tumor Ag-specific human CD8+ T-cell response. The gene discussed is CD8A; the disease is neoplasm.